J Hepatobiliary Pancreat Sci. 2021 May 15. doi: 10.1002/jhbp.986. Online ahead of print.
ABSTRACT
BACKGROUND/PURPOSE: The current study aimed to develop a prediction model using a multi-marker panel as a diagnostic screening tool for pancreatic-ductal-adenocarcinoma.
METHODS: Multi-center cohort of 1,991 blood samples were collected from January 2011 to September 2019, of which 609 are normal, 145 are other-cancer (colorectal, thyroid, and breast cancer), 314 are pancreatic-benign-disease, and 923 are pancreatic-ductal-adenocarcinoma. The automated multi-biomarker Enzyme-Linked Immunosorbent Assay kit was developed using three potential biomarkers, LRG1, TTR, and CA 19-9. Using a logistic regression model trained on training data set, the predicted values for pancreatic-ductal-adenocarcinoma were obtained, and the result was classified into one of the three risk groups: low, intermediate, and high. The five covariates used to create the model were sex, age, and three biomarkers.
RESULTS: Participants were categorized into four groups as normal (n=609), other-cancer (n=145), pancreatic-benign-disease (n=314), and pancreatic-ductal-adenocarcinoma (n=923). The normal, other-cancer, and pancreatic-benign-disease groups were clubbed into the non-pancreatic-ductal-adenocarcinoma group (n=1068). The positive and negative predictive value, sensitivity, and specificity were 94.12, 90.40, 93.81, and 90.86, respectively.
CONCLUSIONS: This study demonstrates a significant diagnostic performance of the multi-marker panel in distinguishing pancreatic-ductal-adenocarcinoma from normal and benign pancreatic disease states, as well as patients with other cancers.
PMID:33991409 | DOI:10.1002/jhbp.986
